Exercise On Bone Metabolism Markers In Chronic Kidney Disease

Aerobic Versus Resistance Exercise On Bone Metabolism Markers In Chronic Kidney Disease

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07628621

Acronym

intervention

Enrollment

Registered

2026-06-05

Start date

2025-12-01

Completion date

2026-05-30

Last updated

2026-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases

Brief summary

Sixty chronic kidney disease patients, Measurement of bone turnover markers done prior to the study and at the end of the study after 6 months.

Detailed description

Sixty chronic kidney disease patients, Measurement of bone turnover markers done prior to the study and at the end of the study after 6 months. Participants included in two groups. Group (A) received resisted exercise training on some resistance machines where; group (B) received treadmill exercise training.

Interventions

OTHERresisted exercise training on some resistance machines

resistance exercises on some resistance machines, 3 sessions of exercise training /week

OTHERtreadmill exercise training

treadmill aerobic exercise (intensity equal 60-80 % of each individual maximum heart rate)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Masking description

double

Intervention model description

Participants included in two groups. Group (A) received resisted exercise training on some resistance machines where; group (B) received treadmill exercise training

Eligibility

Sex/Gender

ALL

Age

30 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Non-smokers, * no alcohol consumption * no intake of hormone replacement therapy * mass index ranged from 20-24 kg/m2.

Exclusion criteria

* diabetes disorders * hypertension disorders * cardiac disorders * musculoskeletal disorders * endocrine disorders * intake of medications that may affect bone metabolism.

Design outcomes

Primary

Measure	Time frame	Description
serum osteoprotegerin (OPG)	at baseline and after six month	An overnight fasting venous blood sample was drained, centrifuged and stored at -70 °C
receptor activator of nuclear factor kappa B ligand	at baseline and after six month	An overnight fasting venous blood sample was drained, centrifuged and stored at -70 °C

Secondary

Measure	Time frame	Description
Bone mineral density (BMD)	at baseline and after six month	BMD of lumbar spine (L1-L4), proximal femur and distal radius was measured with dual-energy X-ray absorptiometry (DEXA).

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 6, 2026